Table 7– Association between the duration of treatment and treatment success by multidrug-resistant tuberculosis (MDR-TB) patient group
Cases nAdjusted OR# (95%CI)Cases nAdjusted OR# (95%CI)Cases nAdjusted OR# (95%CI)Cases nAdjusted OR# (95%CI)
Duration of intensive phase months
 1–4.019241.0 (reference)991.0 (reference)331.0 (reference)551.0 (reference)
 4.1–6.52742.8 (0.8–9.7)823.2 (0.8–13.6)410.9 (0.2–4.5)416.1 (0.6–62)
 6.6–9.02443.1 (1.1–8.3)799.8 (1.9–49)360.6 (0.1–4.1)3771.0 (5.2–200)
 9.1–20.03472.1 (0.9–5.1)1554.1 (1.5–11.2)550.4 (0.1–2.0)775.1 (1.2–21)
Total duration of treatment months
 6.0–15.04431.0 (reference)2791.0 (reference)541.0 (reference)871.0 (reference)
 15.1–20.021713.6 (1.7–7.9)2603.1 (1.0–9.1)472.4 (0.4–14.3)792.0 (0.3–11.7)
 20.1–25.04845.9 (3.0–11.5)2027.7 (3.8–15.7)602.1 (0.7–6.5)615.5 (1.7–17.6)
 25.1–30.01472.8 (1.2–6.9)656.0 (2.3–15.6)244.1 (0.9–19.4)215.8 (1.3–25.1)
 30.1–36.0611.8 (0.6–5.6)172.9 (0.7–12.2)131.1 (0.2–5.2)101.3 (0.2–7.8)
  • MDR-TB: multidrug-resistant TB (resistance to at least isoniazid and rifampicin); MDR-TB only: MDR-TB, but susceptible to fluoroquinolones, amikacin/kanamycin and capreomycin (at least one second-line injectable drug tested); MDR-TB+INJr: MDR-TB plus resistance to amikacin/kanamycin and/or capreomycin, but susceptible to fluoroquinolones; MDR-TB+FQr: MDR-TB plus resistance to any fluoroquinolone, but susceptible to amikacin/kanamycin and/or capreomycin (at least one second-line injectable drug tested); XDR-TB: extensively drug-resistant tuberculosis (MDR-TB plus resistance to any fluoroquinolone and any second-line injectable drug (amikacin/kanamycin and/or capreomycin)). #: Odds ratios of treatment success versus treatment failure or relapse adjusted for age, sex, HIV infection, previous TB treatment, previous MDR treatment (treatment for >1 month with two or more second-line drugs) and extent of disease. See Methods and [17] for treatment outcome definitions. : The initial part of a course of treatment during which an injectable drug is given.